Carbergoline for Antipsychotic Induced Hyperprolactinemia.

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Scizophrenia

In brief

The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia. The main question it aims to answer : Is the severity of positive and negative symptoms affected by the use of cabergoline? Researchers will compare cabergolin to placebo to see if positive and negative symptoms are equel in both groups. Participants will, in a blinded manor, take either placebo tablets or cabergoline for 12 weeks. The severity of positive and negative symptoms will be evaluated before and after the intervention in both groups.

Key facts

Study ID

NCT07386080

Run by

Zealand University Hospital

People needed

146

Starts

2026-05-01

Expected to finish

2029-05-01

Last updated by the study team

2026-02-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• receiveing antipsychotic treatment for at least 3 months for a schizophrenia spectrum disorder
• Prolactin levels > URL
• symptoms of hyperprolactinemia according to he UKU side effect scale (Udvalg for Klinisk Undersøgelser)
• no suicide ideation at time of recruitment (≤ 2 Columbia-Suicide Serverity Rating Scale)

You may not qualify if…

• patients that has previously responded unfavorably to treatment with a dopamine receptor agonist.
• The use of recreational drugs that may give hyperprolactinemia.

Where it is running

• Zealand University Hospital — Køge, Region Sjælland, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.